61735-51-1 Usage
Uses
Used in Organic Chemistry Research:
1-IODO-5-METHOXYNAPHTHALENE is used as a precursor for the synthesis of various other organic compounds, contributing to the development of new chemical entities and reactions.
Used in Pharmaceutical Research:
1-IODO-5-METHOXYNAPHTHALENE is used as a building block for the development of new drugs, playing a crucial role in the discovery and design of innovative pharmaceuticals.
Used in Production of Fluorescent Dyes and Pigments:
1-IODO-5-METHOXYNAPHTHALENE is used as a component in the production of fluorescent dyes and pigments, owing to its fluorescent properties, which are valuable in various applications such as bioimaging and diagnostics.
Used in Material Science:
1-IODO-5-METHOXYNAPHTHALENE is used in the production of advanced materials and polymers, where its unique properties contribute to the creation of novel materials with specific characteristics for various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 61735-51-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,7,3 and 5 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 61735-51:
(7*6)+(6*1)+(5*7)+(4*3)+(3*5)+(2*5)+(1*1)=121
121 % 10 = 1
So 61735-51-1 is a valid CAS Registry Number.
61735-51-1Relevant academic research and scientific papers
Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors
O'Meara, Jeff A.,Yoakim, Christiane,Bonneau, Pierre R.,B?s, Michael,Cordingley, Michael G.,Déziel, Robert,Doyon, Louise,Duan, Jianmin,Garneau, Michel,Guse, Ingrid,Landry, Serge,Malenfant, Eric,Naud, Julie,Ogilvie, William W.,Thavonekham, Bounkham,Simoneau, Bruno
, p. 5580 - 5588 (2007/10/03)
A series of novel 8-substituted dipyridodiazepinone-based inhibitors were investigated for their antiviral activity against wild type human immunodeficiency virus (HIV-1) and the clinically prevalent K103N/Y181C mutant virus. Our efforts have resulted in a series of benzoic acid analogues that are potent inhibitors of HIV-1 replication against a panel of HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs). Furthermore, the combination of good antiviral potency, a broad spectrum of activity, and an excellent pharmacokinetic profile provides strong justification for the further development of compound 7 as a potential treatment for wild type and NNRT1-resistant HIV-1 infection.
